Pdt Partners, LLC Atreca, Inc. Transaction History

Pdt Partners, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$1.61 - $5.2 $154,440 - $498,815	-95,926 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$2.87 - $6.29 $38,173 - $83,663	13,301 Added 16.1%	95,926 $291,000
Q3 2021 Nov 15, 2021	BUY	$4.91 - $9.07 $139,566 - $257,814	28,425 Added 52.44%	82,625 $515,000
Q2 2021 Aug 16, 2021	BUY	$7.82 - $13.8 $142,081 - $250,732	18,169 Added 50.43%	54,200 $462,000
Q1 2021 May 17, 2021	BUY	$13.0 - $19.34 $468,403 - $696,839	36,031 New	36,031 $552,000

1.04M

Ticker BCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,876,000
Description
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-10...

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Pdt Partners, LLC with notifications on news.